BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that NXC-201 treatment...
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated...
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today...
Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation...
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s DiseaseROCHESTER, N.Y.,...
iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual ConferenceNASHUA, N.H., March 23, 2023 (GLOBE...
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,...
Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to...
Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3...
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients...
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by...
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in...
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce...
HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Preprint of results from animal study shows restriction of tumor growth in...
Results from survey of Urea Cycle Disorders (UCD) healthcare providers show taste and odor were the most important attributes when...
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, March 22, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a...
2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2...
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,...